All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
National Collaborating Centre for Mental Health (UK). Alcohol-Use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence. Leicester (UK): British Psychological Society (UK); 2011. (NICE Clinical Guidelines, No. 115.)
Alcohol-Use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence.
Show detailsAppendix 17a. Organisation of care forest plots
Case management versus treatment as usual
Number of participants non-abstinent (PDF, 56K)
Drinking frequency (PDF, 56K)
Appendix 17b. Rehabilitation forest plots
Residential rehabilitation versus outpatient care
Abstinence (PDF, 62K)
Alcohol consumption outcomes (PDF, 62K)
Lapse (non-abstinence) (PDF, 63K)
Drinking frequency (PDF, 63K)
Residential rehabilitation versus day hospital
Abstinence (PDF, 63K)
Alcohol consumption outcomes (PDF, 63K)
Relapse (PDF, 64K)
Lapse (non-abstinence) (PDF, 64K)
Drinking frequency (PDF, 66K)
Attrition (number not retained in treatment) (PDF, 66K)
Day hospital versus outpatient
Percent days abstinent at 3-month follow-up (PDF, 70K)
Drinks per drinking day at 3-month follow-up (PDF, 66K)
Day hospital versus outpatient
Relapse (PDF, 61K)
Short-duration versus longer-duration inpatient
Lapse (non-abstinence) (PDF, 64K)
Number consuming alcohol 60 to 90% of the time at 3-month follow-up (PDF, 64K)
Number consuming alcohol 60 to 90% of the time at 6-month follow-up (PDF, 63K)
Number consuming alcohol less than 60% of the time at 3-month follow-up (PDF, 63K)
Number consuming alcohol less than 60% of the time at 6-month follow-up (PDF, 63K)
Appendix 17c. Psychological interventions forest plots
Motivational techniques
Motivational techniques versus control (PDF, 175K)
Motivational techniques versus other intervention (PDF, 129K)
Twelve-step facilitation
Twelve-step facilitation versus other intervention (PDF, 119K)
Twelve-step facilitation versus twelve-step facilitation (PDF, 84K)
Cognitive behavioural therapies
Cognitive behavioural versus treatment as usual or control (PDF, 90K)
Cognitive behavioural versus other intervention (PDF, 174K)
Cognitive behavioural versus cognitive behavioural (PDF, 134K)
Behavioural therapies
Behavioural therapies versus treatment as usual or control (PDF, 82K)
Behavioural therapies versus other intervention (PDF, 116K)
Social network/environment-based therapies
Social network/environment-based therapies versus control (PDF, 107K)
Social network/environment based therapies versus other intervention (PDF, 85K)
Social network/environment-based therapies versus social network/environment-based therapies (PDF, 100K)
Couples therapy
Couples therapy versus other intervention (PDF, 124K)
Behavioural couples therapy versus other couples therapy (PDF, 93K)
Intensive couples therapy versus brief couples therapy (PDF, 93K)
Parental skills + behavioural couples therapy (PSBCT) versus behavioural couples therapy alone (PDF, 65K)
Contingency management
Contingency management versus control (PDF, 100K)
Contingency management versus standard care (treatment as usual) (PDF, 73K)
Contingency management versus other intervention (PDF, 100K)
Short-term psychodynamic therapy
Short-term psychodynamic therapy versus other intervention (PDF, 73K)
Multi-modal intervention
Multi-modal versus other intervention (PDF, 100K)
Self-help
Self-help versus self-help (PDF, 66K)
Psychoeducational intervention
Psychoeducational versus other intervention (PDF, 132K)
Appendix 17d. Pharmacological interventions forest plots
Acamprosate for alcohol-use disorders
Acamprosate versus placebo (PDF, 243K)
Naltrexone
Naltrexone versus placebo (PDF, 274K)
Naltrexone versus acamprosate (PDF, 205K)
Naltrexone + sertraline versus naltrexone (PDF, 190K)
Naltrexone versus topiramate (PDF, 187K)
Naltrexone + acamprosate versus placebo (PDF, 188K)
Naltrexone + acamprosate versus acamprosate (PDF, 187K)
Naltrexone + acamprosate versus naltrexone (PDF, 183K)
Disulfiram
Disulfiram versus placebo (PDF, 190K)
Disulfiram versus acamprosate (PDF, 197K)
Disulfiram versus naltrexone (PDF, 208K)
Disulfiram versus topiramate (PDF, 186K)
Disulfiram + counselling versus counselling (PDF, 169K)
- Alcohol use disorders: harmful drinking and alcohol dependence: Evidence Update January 2013: A summary of selected new evidence relevant to NICE clinical guideline 115 'Alcohol use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence' (2011)
- 2019 surveillance of alcohol-use disorders (NICE guidelines PH24 and CG115)
- Clinical evidence forest plots - Alcohol-Use DisordersClinical evidence forest plots - Alcohol-Use Disorders
Your browsing activity is empty.
Activity recording is turned off.
See more...